Indaptus Therapeutics, INC 8-K filings

Indaptus Therapeutics reported Q2 2026 results, highlighting a significant reduction in operating expenses and net loss, alongside a $12 million private placement, while discontinuing its Decoy20 clinical study and exploring strategic alternatives.

Indaptus Therapeutics has entered into a definitive agreement to raise $12 million through the sale of 20 million shares of common stock to non-U.S. accredited investors.

Indaptus Therapeutics reports the resignation of two directors and the transition of its Chief Operating Officer to a consulting role.

Indaptus Therapeutics reported first quarter 2026 financial results, highlighting reduced operating expenses but a significant increase in net cash used in operating activities, alongside a strategic review of its development programs.

Indaptus Therapeutics has appointed Tim Ruan and Johnny Fox Arrowsmith to its Board of Directors while announcing the resignation of Matthew McMurdo.

Indaptus Therapeutics, Inc. announced the appointment of two new independent directors, Tim Ruan and Dr. Yi Zhang, effective April 22, 2026, and the resignation of Matthew McMurdo.

Indaptus Therapeutics, Inc. has announced the resignation of its CFO, Nir Sassi, and the appointment of Qinglai Lu to its Board of Directors and Yu Ding as the new CFO.

Indaptus Therapeutics announced a significant change in control with a group of purchasers acquiring a majority stake in preferred stock, leading to a new CEO and board chairman.

Indaptus Therapeutics stockholders approved a reverse stock split, increased authorized shares, and a change of control to David E. Lazar, paving the way for strategic transactions.

Indaptus Therapeutics repriced over 1.6 million warrants to $1.75 per share, securing voting agreements from holders for upcoming proposals.

Indaptus Therapeutics announced significant salary reductions for its Co-CEO and Chief Science Officer, while a key board member rescinded his resignation.

Indaptus Therapeutics, Inc. announced the appointment of financial expert David Natan to its Board of Directors and Audit Committee, increasing the board size to nine members.

Three directors, Michael Newman, Mark Gilbert, and Anthony Maddaluna, have resigned from the Indaptus Therapeutics Board, effective upon the approval of new nominees.

Indaptus Therapeutics completes a $6 million preferred stock financing, bringing in David E. Lazar as Co-CEO and Chairman, alongside significant executive compensation modifications and a planned reverse stock split.

Indaptus Therapeutics reported Q3 2025 financial results, including a pause in clinical trial enrollment for Decoy20 and tislelizumab combination therapy, alongside a $2.3 million capital raise.

Indaptus Therapeutics announced mixed clinical trial updates for its INDP-D101 study, including a transient partial response and disease progression in early combination therapy, alongside a $5.7 million capital raise.

Indaptus Therapeutics reports Q2 2025 financial results, highlighting the initiation of a key combination clinical trial and a $5.7 million capital raise to support ongoing development.

Indaptus Therapeutics, Inc. announced the automatic conversion of $5.7 million in convertible notes into common stock and warrants, following shareholder approval of the private placement terms, including related party participation.

Indaptus Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a prior deficiency and securing its listing.

Indaptus Therapeutics, a clinical-stage biotechnology company, has successfully completed a private placement raising $5.7 million to advance its research and development, including a Phase 1b/2 clinical trial.

Indaptus Therapeutics, Inc. has announced the effectiveness of a 1-for-28 reverse stock split of its common stock, primarily aimed at regaining compliance with Nasdaq's continued listing requirements and attracting institutional investors.

Indaptus Therapeutics, a clinical-stage biotechnology company, has announced the initial closing of a private placement, raising $2.3 million through the sale of convertible notes and warrants, with proceeds earmarked for research and development, including a Phase 1b/2 clinical trial.

Indaptus Therapeutics, Inc. announced that its shareholders approved all proposals at the Annual Meeting held on June 10, 2025, including the election of three Class I directors and a significant reverse stock split.

Indaptus Therapeutics announced its Q1 2025 financial results, highlighting progress in its clinical and research programs, including the initiation of a Phase 1b/2 combination study of Decoy20 with Tislelizumab and expansion of its patent portfolio.

Indaptus Therapeutics announces its Q4 and year-end 2024 financial results, highlighting clinical progress in its Decoy20 Phase 1 trial and a corporate update.

Indaptus Therapeutics enters into a Standby Equity Purchase Agreement with YA II PN, LTD. for up to $20 million in funding over the next 36 months.

Indaptus Therapeutics has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Indaptus Therapeutics has announced a $2.25 million private placement of common stock and warrants priced at-the-market under Nasdaq rules.

Indaptus Therapeutics has successfully raised $2.135 million through a registered direct offering and concurrent private placement of common stock and warrants.

Indaptus Therapeutics reported its third quarter 2024 financial results, highlighted a clinical supply agreement with BeiGene, and provided an update on its clinical trial progress.